[{"indications": "Indications\u00a0type 2 diabetes mellitus", "name": "GLIBENCLAMIDE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.1 Drugs used in diabetes", "6.1.2 Antidiabetic drugs", "6.1.2.1 Sulfonylureas"], "cautions": "Cautions\u00a0\n(From 6.1.2.1 Sulfonylureas: British National Formulary)\nCautions\u00a0Sulfonylureas can encourage weight gain and should be prescribed only if poor control and symptoms persist despite adequate attempts at dieting; metformin (section 6.1.2.2) is considered the drug of choice in obese patients. Caution is needed in the elderly and in patients with G6PD deficiency (section 9.1.5).; interactions: Appendix 1 (antidiabetics)", "side-effects": "Side-effects\u00a0see notes above", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4168.htm", "doses": ["Initially 5\u00a0mg daily with or immediately after breakfast,\r\ndose adjusted according to response (elderly avoid, see notes above); max. 15\u00a0mg daily"], "pregnancy": "Pregnancy\u00a0\n(From 6.1.2.1 Sulfonylureas: British National Formulary)\nPregnancy\u00a0The use of sulfonylureas in pregnancy should generally be avoided because of the risk of neonatal hypoglycaemia; however, glibenclamide can be used during the second and third trimesters of pregnancy in women with gestational diabetes, see section 6.1.2."}]